false
0002019505
0002019505
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
November 17, 2026
Date of Report (Date of earliest event reported)
Health In Tech, Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
|
001-42449 |
|
87-3545722 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
701 S. Colorado Ave, Suite 1
Stuart, FL |
|
34994 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (888) 373-0333
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Class A Common Stock, $0.001 par value per share |
|
HIT |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed in
a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 12, 2026 and in
the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed with the SEC on November 13, 2026, respectively, the
stockholders of Health In Tech, Inc., a Nevada corporation (the “Company”), elected Tim Cortes, age 60, to the Company’s
Board of Directors (the “Board”), effective as of November 10, 2026, and the Board appointed the Chief Executive Officer of
the Company, Sanjay Shrestha, age 52, and Christina R. Valauri, age 71, to the Board, in each case effective as of November 12, 2026.
Mr. Shrestha, Mr. Cortes and Ms. Valauri will each serve as a member of the Board for a one-year term and until a successor is duly elected
and qualified or until his or her earlier death, resignation, disqualification, or removal. There are no arrangements or understandings
between any of Mr. Shrestha, Mr. Cortes or Ms. Valauri and the Company or any other person pursuant to which he or she was selected as
a director. The Board has appointed Mr. Cortes, as an independent director, to the Audit Committee, to the Nominating and Corporate Governance
Committee and as Chair of the Compensation Committee of the Board. The Board has also appointed Ms. Valauri, as an independent director,
to serve on the Audit Committee, the Nominating and Corporate Governance Committee and the Compensation Committee of the Board. There
are no related party transactions involving Mr. Shrestha, Mr. Cortes or Ms. Valauri that would require disclosure under Item 404(a) of
Regulation S-K.
Effective upon their respective
appointments, Mr. Cortes and Ms. Valauri each became eligible to receive compensation in accordance with the Company’s non-employee
director compensation policy which was described in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026.
In connection with each of Mr. Cortes’ and Ms. Valauri’s selection as a director of the Board, the Company intends to enter
into an indemnification agreement with each party in the same form as the indemnification agreements the Company has entered into with
its other directors and officers. The indemnification agreements provide the Company’s executive officers and directors with contractual
rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under Nevada law, subject to certain
exceptions contained in those agreements. There are no other material plans, contracts or arrangements to which either of Mr. Cortes or
Ms. Valauri is a party or in which he or she participates that was entered into in connection with his or her selection as a director
of the Board.
Item 7.01 Regulation FD Disclosure.
On November 17, 2026 and November
18, 2026, respectively, the Company issued a press release announcing the appointment of Ms. Valauri to the Board and a press release
announcing the election of Mr. Cortes to the Board. A copy of the press release relating to Ms. Valauri’s appointment is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the press release relating to Mr. Cortes’ election is furnished
as Exhibit 99.2 to this Current Report on Form 8-K. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the
attached Exhibit 99.1 and Exhibit 99.2 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall
not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of
any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated November 17, 2026. |
| 99.2 |
|
Press Release, dated November 18, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: November 18, 2026 |
|
| |
|
| HEALTH IN TECH, INC. |
|
| |
|
|
| By: |
/s/ Julia (LinLin) Qian |
|
| Name: |
Julia (LinLin) Qian |
|
| Title: |
Chief Financial Officer |
|
Exhibit 99.1
Health In Tech Appoints Wall Street Research
and Capital Markets Veteran Christina R. Valauri to Board of Directors
Seasoned public company director and senior
capital markets executive brings more than 30 years of financial services leadership, corporate governance and strategic advisory experience,
includes senior roles at Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais
STUART, Fla., November 17, 2026 /PRNewswire/ -- Health In Tech,
Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced
the appointment of Christina R. Valauri to its Board of Directors as an independent director, effective November 12, 2026. Ms. Valauri
will serve as a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of
the Board.
Ms. Valauri brings more than three decades of Wall Street and capital
markets analytical, management and leadership experience, having held Managing Director and senior executive positions at prominent global
financial institutions, including Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais. Her leadership roles included
Global Director of Equity Research at Cantor Fitzgerald and Co-Head of Equity Capital Markets at First Albany where she
also served on the firm’s operating committee. Throughout her career, she has led global research organizations, driven strategic
business transformation and established regulatory and supervisory frameworks. A recognized healthcare investment research professional,
Ms. Valauri was ranked No. 1 in the biomedical and biotechnology sector in The Wall Street Journal’s “Best on the Street”
All-Star Analyst Survey.
Sanjay Shrestha, Chief Executive Officer of Health In Tech, commented:
“Christina brings a valuable combination of Wall Street leadership,
healthcare industry insight and public company governance experience,” said Sanjay Shrestha, Chief Executive Officer of Health In
Tech. “She understands how institutional investors evaluate management teams, business models, competitive positioning and the ability
to translate innovation into sustainable growth. Her experience advising emerging healthcare companies also brings a practical perspective
on commercialization and the organizational capabilities needed to scale. As we expand our AI-enabled marketplace, strengthen our distribution
relationships and advance our product portfolio, we believe Christina’s insights will help our Board evaluate strategic opportunities,
support disciplined execution and guide the Company toward long-term shareholder value creation.”
Throughout her career, Ms. Valauri has led international equity research
teams across New York, London, Hong Kong and Toronto, built and managed institutional research organizations and implemented business
transformation initiatives. She also brings substantial experience in corporate governance, regulatory oversight and risk management.
As a senior research executive and broker-dealer manager, she established regulatory and supervisory frameworks designed to uphold SEC
and FINRA requirements and corporate governance best practices.
Ms. Valauri spent more than 16 years as a senior sell-side equity research
analyst covering pharmaceutical, biotechnology and medical technology companies in the U.S. and internationally, including at PaineWebber.
Her analytical experience encompasses evaluating emerging healthcare technologies, assessing business models and competitive dynamics,
and identifying commercial opportunities and investment considerations. This research background, combined with her understanding of institutional
investor expectations, provides valuable insight into the opportunities and challenges facing technology-driven healthcare companies.
Ms. Valauri currently serves as an independent director of two other
Nasdaq-listed companies, Valion Bio, Inc. (Nasdaq: VBIO) since July 2024 and Precipio, Inc. (Nasdaq: PRPO) since January 2024, bringing
additional public company governance experience to our Board. She is also the Founder and CEO of Sagestone Advisory LLC, where she advises
emerging companies on business strategy, capital markets positioning and growth initiatives. Additionally, she serves as a Mentor and
Guest Lecturer at Weill Cornell Medicine’s BioVenture eLab, where she previously served as Entrepreneur in Residence, supporting the development
and commercialization of innovative healthcare technologies.
Ms. Valauri holds an Executive MBA from Cornell University and a Bachelor
of Arts in Biology from Reed College. She is also a National Association of Corporate Directors (NACD) Certified Director.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Health In Tech,
Inc.’s (“Health In Tech,” “we,” “us” or “our”) business strategy, product development and innovation,
growth prospects, and future operating and financial performance. In some cases, forward-looking statements can be identified by terminology
such as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “could,” “would,” “project,” “plan,” “target”
or similar expressions that are predictions of or indicate future events or trends and that do not relate solely to historical matters.
Forward-looking statements in this press release include, but are not limited to, statements regarding the expected benefits of the Company’s
leadership transition; the Company’s strategic priorities, including accelerating organic growth and commercial execution, expanding adoption
of its solutions and strengthening distribution and carrier partnerships; the Company’s intention to evaluate and pursue potential acquisitions,
strategic investments, partnerships and other business opportunities; and the Company’s ability to create long-term shareholder value.
These forward-looking statements are based on current expectations
and beliefs concerning future events and developments and their potential effects on Health In Tech and are subject to numerous known
and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Health In Tech’s control, that
could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These factors include,
but are not limited to: risks related to the leadership transition, including our ability to successfully integrate new management and
retain key personnel; our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions
on favorable terms, or at all; our ability to obtain funding for our operations and to enhance our current systems and expand our service
offerings; our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements; the success,
cost and timing of our product development activities; our ability to attract and retain key personnel and qualified employees; our ability
to attract new customers and to develop new, and enhance existing, products and services; the impact of competition in our industry and
innovation by our competitors; risks related to cybersecurity incidents or other network disruptions; risks related to the use of third-party
artificial intelligence; our ability to comply with new or modified laws and regulations applicable to our business, including with respect
to the insurance services industry and data privacy requirements; our ability to protect our intellectual property rights and maintain
and build our brand; the future trading price of our common stock; and other risks and uncertainties described in the “Risk Factors”
section of our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S.
Securities and Exchange Commission.
Any forward-looking statement made in this press release speaks only
as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for Health In Tech
to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except
as required by applicable law, Health In Tech does not undertake, and expressly disclaims, any obligation to update or revise publicly
any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
About Health In Tech
Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform
company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification,
and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies,
licensed brokers, Managing General Underwriter (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s
platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing
functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and
reporting integration.
Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com
Exhibit 99.2
Health In Tech Appoints Tim Cortes as Independent
Director, Chair of the Compensation Committee
Technology veteran brings more than 30 years
of experience in technology innovation, clean energy, power systems, and product development to support Health In Tech’s AI strategy and
product innovation initiatives.
STUART, Fla. — November 18, 2026 — Health In Tech,
Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced
that Tim Cortes has joined the Company’s Board of Directors as an independent director. In connection with his election to the Board,
Mr. Cortes has also been appointed Chair of the Board’s Compensation Committee, as a member of the Audit Committee and as a member
of the Nominating and Corporate Governance Committee.
Mr. Cortes brings more than three decades of experience as a visionary
technology and innovation leader, with extensive expertise spanning clean energy, power systems, advanced technology development, and
product innovation. Throughout his career, he has focused on developing and commercializing technology solutions, leading product development
initiatives, and helping organizations navigate complex technology transformations.
His experience in technology strategy, innovation, engineering, and
product development is expected to bring valuable perspective to Health In Tech as the Company accelerates its AI initiatives, advances
its technology infrastructure, expands its product portfolio, and pursues new opportunities to transform the self-funded healthcare insurance
marketplace.
As Health In Tech continues to invest in artificial intelligence, automation,
data-driven solutions, and next-generation insurance technology, Mr. Cortes’s experience in bringing innovative technologies from
concept through product development and commercialization is expected to complement the Company’s strategic priorities. His background
will provide an additional perspective as the Company evaluates new AI applications, develops new products, and pursues opportunities
to improve efficiency and create greater value for brokers, third-party administrators, managing general underwriters, carriers, and employers.
As Chair of the Compensation Committee, Mr. Cortes will also contribute
to the Board’s oversight of executive compensation strategy, leadership development, and alignment of management incentives with
the Company’s long-term objectives and shareholder interests.
“We are very pleased to welcome Tim Cortes to Health In Tech’s
Board of Directors,” said Sanjay Shrestha, Chief Executive Officer of Health In Tech. “Tim brings more than 30 years of technology
and innovation leadership, with a particularly strong background in clean energy, power systems, and product development. As we enter
our next phase of growth, we are focused on leveraging artificial intelligence across our business, accelerating our innovation initiatives,
and bringing new technology-driven products and solutions to market. We believe Tim’s experience in developing and commercializing
innovative technologies will be extremely valuable as we execute on these priorities. We also look forward to benefiting from his leadership
as Chair of our Compensation Committee as we continue to strengthen corporate governance and align our leadership team around long-term
shareholder value creation.”
The appointment reflects Health In Tech’s continued commitment
to strengthening its Board with experienced independent leaders who bring complementary expertise in technology, innovation, corporate
governance, and strategic growth.
About Health In Tech
Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform
company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification,
and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies,
licensed brokers, managing general underwriters (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s
platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing
functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and
reporting integration.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Health In Tech,
Inc.’s (“Health In Tech,” “we,” “us” or “our”) business strategy, product development and innovation,
growth prospects, and future operating and financial performance. In some cases, forward-looking statements can be identified by terminology
such as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “could,” “would,” “project,” “plan,” “target,”
“objective” or similar expressions that are predictions of or indicate future events or trends and that do not relate solely
to historical matters. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected
benefits of the Company’s leadership transition; the Company’s strategic priorities, including accelerating organic growth and commercial
execution, expanding adoption of its solutions, leveraging artificial intelligence and strengthening distribution and carrier partnerships;
the Company’s intention to evaluate and pursue potential acquisitions, strategic investments, partnerships and other business opportunities;
and the Company’s ability to create long-term shareholder value.
These forward-looking statements are based on current expectations
and beliefs concerning future events and developments and their potential effects on Health In Tech and are subject to numerous known
and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Health In Tech’s control, that
could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These factors include,
but are not limited to: risks related to the leadership transition, including our ability to successfully integrate new management and
retain key personnel; our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions
on favorable terms, or at all; our ability to obtain funding for our operations and to enhance our current systems and expand our service
offerings; our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements; the success,
cost and timing of our product development activities; our ability to attract and retain key personnel and qualified employees; our ability
to attract new customers and to develop new, and enhance existing, products and services; the impact of competition in our industry and
innovation by our competitors; risks related to cybersecurity incidents or other network disruptions; risks related to the use of third-party
artificial intelligence; our ability to comply with new or modified laws and regulations applicable to our business, including with respect
to the insurance services industry and data privacy requirements; our ability to protect our intellectual property rights and maintain
and build our brand; the future trading price of our common stock; and other risks and uncertainties described in the “Risk Factors”
section of our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S.
Securities and Exchange Commission.
Any forward-looking statement made in this press release speaks only
as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for Health In Tech
to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except
as required by applicable law, Health In Tech does not undertake, and expressly disclaims, any obligation to update or revise publicly
any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com